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Background/aims: Reported associations of controlled ovarian hyperstimulation response (COH) with genotypes of
the Ser680Asn (N680S) polymorphism in the follicle stimulating hormone receptor (FSHR) gene have conflicting
results.
Methods: PubMed and Embase databases were searched for studies that investigated the N680S polymorphism in
the FSHR gene in COH. Parameters used to examine ovarian response were poor and hyper-responses to COH.
Using the meta-analytic approach, we estimated ovarian response risk (odds ratio [OR] with 95% confidence intervals)
according to genotype.
Results: Our findings showed that SS genotype carriers were most likely to be poor responders (OR 1.61, p = 0.08)
compared to the NN and NS genotypes which showed no associations (OR 0.93-0.95, p = 0.75-0.78). Heterogeneity
of these pooled ORs warranted examining its sources. We detected outlying studies in each of the three N680S
genotypes. Omitting these outliers erased the heterogeneity of the recalculated pooled outcomes. It also materially
altered the SS effects where carriers became slightly unlikely to be poor responders (OR 0.90, p = 0.52). The S
allele carrier effect was modulated for poor responders (OR 1.24, p = 0.39) in the Non-Hispanic Caucasian (NHC)
subgroup. The likelihood of the S allele carriers (OR 1.47, p = 0.02) and the unlikelihood of the N allele carriers
(OR 0.64, p = 0.007) were significant in our hyper-response findings. Confined to NHC retained significance of
the S allele effects (OR 1.57, p = 0.01) but not among the N allele carriers (OR 0.68, p = 0.18).
Conclusions: In summary, this is a meta-analytical confirmation of the FSHR SS genotype role in COH response.
Hyper-responder analysis strengths lie on the non-heterogeneity and robustness of its results. Non-robustness
and heterogeneity of the poor-responder results compose its limitations. Thus, poor response findings probably
require caution as to the interpretation as a susceptibility marker for ovarian response.
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In vitro fertilization (IVF) is a multi-step process involving
collection of oocyte-containing follicles after controlled
ovarian hyperstimulation (COH) with rFSH (recombinant
Follicle-stimulation hormone). Further steps involve
oocyte fertilization, embryo development, embryo transfer
to the uterus, and implantation. All these steps are critical
for successful IVF [1]. An initial critical step of this
complex procedure is the COH, aiming to safely obtain
an adequate number of high-quality oocytes, so as to
allow selection of the most viable embryo for transfer
[1,2]. However, women submitted to this procedure yield
different numbers of oocytes. Poor responders provide no
more than 4-5 oocytes. Those with 6-15 oocytes are
normal responders and those with >15 oocytes are hyper-
responders [3,4]. Poor responses result in retrieved
oocytes reduced number and hyper-response may lead
to ovarian hyperstimulation syndrome (OHSS). Poor
response may warrant repeated stimulation cycles to
obtain appropriate number of oocytes. In contrast,
good response is modulated to avoid hyperstimulation
[5]. Thus, the patients advanced identification will
elicit these responses in order to standard treatment,
which would be clinically beneficial. Several factors
have been proposed to predict ovarian response. These
are: age [6], hormonal status [7], cigarette smoking [8]
and ovarian reserve [6,9]. Apart from these proposed
predictors, polymorphisms in various genes, such as
estrogen receptor alpha (ESR1), cytochrome P450 19A
(CYP19A) and follicle-stimulating hormone (FSH) have
been investigated as markers to predict ovarian re-
sponse [1,10-13]. FSH has been implicated in follicular
growth and maturation, granulosa cell proliferation and
in estradiol/aromatase synthesis [14]. FSH effects are
mediated by FSH receptor (FSHR), a G-protein-coupled
receptor expressed in granulosa cells [15] which medi-
ates FSH signal transduction through adenylate cyclase
activation and elevation of intracellular cAMP [16]. The
FSHR gene is located on chromosome 2p21 spanning a
region of 54 kb [17] and contains one large exon, which
encodes the transmembrane and intracellular domains;
and nine smaller exons, which encode the extracellular do-
main [15]. Two non-synonymous SNPs have been identi-
fied in the coding region of exon 10 of the FSH receptor
gene (http://www.ncbi.nlm.nih.gov/snp/?term=FSHR; Gen-
eID: 2492; Locus tag: HGNC: 3969). The first (rs6165) is
found within the extracellular domain (codon 307) in
which A is substituted by G, changing codon 307 from
threonine (ACT) to alanine (GCT). The second (rs6166)
lies within the intracellular domain (codon 680), in
which G is replaced by A. This leads to an amino acid
change at position 680 from serine (AGT) to asparagine
(AAT) [18]. These two SNPs are related to ovarian re-
sponse and affect gene function by changing the egene product properties and consequently modifying
response to FSH [19]. These polymorphisms are in linkage
disequilibrium (LD), resulting in the most frequent al-
lelic combination of T307-N680 and A307-S680 [20,21].
Many previous studies including a recent meta-analysis
[22] focused on the N680S polymorphism. Clinical studies
have demonstrated that the N680S polymorphism deter-
mines ovarian response to FSH stimulation in patients
undergoing IVF treatment [11,22,23].
Given the conflicting outcomes in the human repro-
duction investigations of the variants in the FSHR gene
[17,24], we performed a meta-analysis to evaluate the
role of the N680S FSHR polymorphism in ovarian
response. Here, we compared the association of inac-
tivating FSHR genotypes in (i) poor and (ii) hyper-
responding women with normal ovarian response.
Materials and methods
Selection of studies
Using the terms, ? FSHR ? , ? follicle stimulating hormone ? ,
? polymorphism ? and ? ovarian stimulation ? , we searched
MEDLINE using PubMed and Embase for associated
studies as of September 12, 2014. References cited in the
retrieved articles were also screened manually to identify
additional eligible studies. Inclusion criteria included: (1)
case ? control study design evaluating the association
between FSHR polymorphisms and ovarian response,
(2) sufficient genotype frequency data presented to calcu-
late the odds ratios (ORs) and 95% confidence intervals
(CIs). (3) Control frequencies (normal/good responders)
must be in Hardy-Weinberg Equilibrium (HWE).
Data extraction
Two investigators, independently, extracted data and
reached consensus on all the items. The following
information was obtained from each publication: first
author ? s name, published year, country of origin, dom-
inant ancestry of the study populations, study design,
context of the study, type of ovarian response, use of
the HWE, addressed LD, FSHR polymorphism studied,
sample source, genotyping approach, matching infor-
mation and genotype data. We extracted data that
belonged to our investigation of ovarian response using
these parameters: (i) number of poor and (ii) hyper-
responders as well as (iii) normal (good/control) re-
sponders. We also calculated frequencies of the variant
allele, deviations of the normal responders from the
HWE. (iv) Rates of pregnancy.
Quality assessment of the studies
We used the Clark-Baudouin Score (CBS) to evaluate
the methodological quality of the included studies [25].
This scale emphasizes statistics (i.e. p values, power and
corrections for multiplicity) and includes genotyping
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addressed in several of the included papers. Thus, we
felt this to be the most appropriate in assessing the
methodological included studies quality. The CBS scores
reach from 0 (worst) to 9 (best) for cohort studies and 0
(worst) to 10 (best) for case-control studies. The score
follows as: case-control studies: (quality is low for <5 and
high for ≥5); cohort studies: (quality is low for <4 and
high for ≥4).
Meta-analysis
Due to the FSHR polymorphisms (T307A and N680S)
were found to be in complete LD [20,21], we only inves-
tigated the N680S polymorphism. Influence of FSHR
N680S polymorphism was estimated using the following
parameters: we examined (i) poor ovarian response, (ii)
hyper-response compared to the (iii) normal or good
responders using the homozygote variant and wild-
type alleles as well as the heterozygote genotype. We
also examined (iv) pregnancy rates. These associations
were expressed as OR, 95% CI.
Raw data for genotype frequencies, without adjustment,
were used for calculating OR study-specific estimates.
The pooled estimates significance was determined by
the Z-test. Pooled estimates were obtained using either
the fixed [26] (in the absence of heterogeneity) or random
[27] (in its presence) effects models. Heterogeneity
between studies was estimated using the χ2-based Q
test [28]. Recognizing the low power of this test [29],
significance threshold was set at p = 0.10. We also
quantified heterogeneity with the I2 statistic which
measures the degree of inconsistency among studies [30].
Significance was set at a p-value of ≤0.05 throughout,
except in heterogeneity estimation. Pooled estimates were
submitted to sensitivity analysis which involved omitting
one study at a time and recalculating the pooled estimates,
to test the summary effect robustness. Subgroup analysis
based on ethnicity was performed on those comprising
of three or more subgroups. Data were analyzed using
Review Manager 5.3 (Copenhagen: Nordic Cochrane
Centre, Cochrane Collaboration, 2014) and SigmaStat
2.3 (Systat Software, San Jose, CA). Most comparisons
in our meta-analysis had less than 10 studies, and be-
cause of the low sensitivity of the qualitative and quanti-
tative tests [31], we did not investigate publication bias.
However, the overall analysis of poor responders had
11 studies; for those, we used Begg ? s test to evaluate
whether the magnitude of the observed association was
related to the variance of each study [32].
Results
Included studies
Figure 1 outlines our study selection process in a flow-
chart following PRISMA (Preferred Reporting Items forSystematic Reviews and Meta-Analyses) guidelines [33].
We identified a total of 215 citations during the initial
search, from which 161 were omitted because they were
not conforming our inclusion criteria. We retrieved the
remaining 54 abstracts which after review, five articles
were excluded. Full-texts of the remaining 49 were
obtained and read including the reference lists. From
these lists, we found five articles with potential inclu-
sion in the meta-analysis. From the 54 full-text articles,
43 were removed, including two studies [3,34] which
control frequencies deviated from the HWE. Under these
circumstances, the total number of articles included in
the meta-analysis was 11 [1,4,13,35-42]. This number
was increased to 13 studies, due to the provision of the
independent data added from Boudjenah et al [1] and
Livshyts et al [39].
The epidemiological features and clinical characteris-
tics of these studies are outlined in Table 1. The publi-
cation years of the included studies ranged from 2003
to 2014. Six studies [1,36,38-40,42] had subjects that
were of non-Hispanic Caucasian (NHC) descendant,
two [13,37] were Hispanic Caucasian (HC) and three
were Asian [4,35,41]. Eight of each 11 articles (72.7%)
addressed HWE and LD, respectively. Based on the
CBS scores, methodological quality of the included papers
was high (mean and standard deviation of 5.82 ? 1.3).
Additional file 1: Table S1 shows the 11 studies from
nine articles [1,4,13,35,37-42] summarizing the genotype
frequencies of the poor responders compared to normal/
good responders. Additional file 2: Table S2 displays the
six studies from five articles [1,13,35,36,40] summarizing
genotype frequencies of the hyper-responders compared
to normal responders.
Overall and subgroup analysis
We found no evidence of publication bias in the overall
analysis of poor responders (p = 0.39-0.94). Table 2 and
Figures 2 and 3 show an overall favoring of the SS geno-
type among the ovarian response groups, significant for
hyper-responders (OR 1.47, p = 0.02) but not for poor
responders (OR 1.61, p = 0.08). Confined to NHC modu-
lated the poor responder effects (OR 1.24, p = 0.39) but
not the hyper-responder effects (OR 1.57, p = 0.01). The N
allele carriers unlikelihood of being ovarian responders
was exemplified among hyper-responders with an overall
significance (OR 0.64, p = 0.007). Of the studies listed in
Table 1, six reported pregnancy rates [3,34,36,38,40,43],
half of these had controls that deviated from the HWE
[3,34,36]. All pregnancy rates pooled effects indicated
absence of associations (data not shown).
Outlier analysis
We sought outlier studies as sources of the heterogeneity
observed in the overall poor responder pooled effects
Figure 1 Flowchart of literature search and study selection.
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outliers, four studies from three articles [4,39,41] in
the S allele, three studies [37,39,41] in the N allele and
one study [4] in the NS genotype. Table 2 shows the re-
sults of removing these outliers followed by re-analysis
which erased heterogeneity (p values for heterogeneity
from < 0.0001 to = 0.78) in all three genotypes and al-
tered the SS genotype effect (OR 0.90, p = 0.52).Sensitivity analysis
Table 3 summarizes the changes in association resulting
from sensitivity treatment. These changes have affected the
poor responder group more than the hyper-responders.
Generally, finding of no associations have been altered to
the likelihood of N allele carriers to be poor responders
with omission of three studies from two articles [39,41].
This pattern was also observed in hyper-responders where
Table 1 Included articles characteristics that examined the FSHR N680S polymorphism association with ovarian response
First author PY [R] Country Ethnic group Sample size Type of ovarian response Used HWE Addressed LD Tissue source Genotyping CBS
Daelemans 2004 [36] Belgium NHC 229 Hyper/controls No Yes blood DNA sequencing 4
Klinkert 2006 [38] Nether-lands NHC 105 Poor, not poor No Yes blood Taqman 5
Livshyts 2009 [39] Ukraine NHC 374 poor, good/controls Yes Yes blood PCR-RFLP 5
Boudjenah 2012 [1] France NHC 427 poor, hyper/controls Yes Yes blood Multiplex PCR 7
Binder 2012 [42] Germany NHC 259 low, control No No blood RT-QPCR 6
Mohiyiddeen 2013 [40] United Kingdom NHC 504 poor, normal, hyper Yes Yes blood Taqman 5
de Castro 2003 [37] Spain HC 102 poor, good Yes Yes blood RT-QPCR 5
de Castro 2004 [13] Spain HC 170 poor, rest of patients, high Yes No blood RT-QPCR 8
Huang 2014 [4] China Asian 1,250 Poor, good responders Yes Yes blood MALDI-TOF 8
Achrekar 2009 [35] India Asian 150 Hyper, not hyper Yes No blood RT-QPCR 5
Yan 2013 [41] China Asian 450 Poor, not poor, hyper, not hyper Yes Yes blood RT-QPCR 6
PY: Publication Year; [R]: Reference; NHC: Non-Hispanic Caucasian; HC: Hispanic Caucasian; HWE: Hardy-Weinberg Equilibrium; LD: Linkage Disequilibrium PCR: Polymerase Chain Reaction; RFLP: Restriction Fragment
Length Polymorphism; RT-QPCR: Real-Time Quality Polymerase Chain Reaction; MALDI-TOF: Matrix Assisted Laser Desorption Ionization-Time-of-Flight; CBS: Clark-Baudouin Score: assessment of methodological quality

















Table 2 Summary of the FSHR N680S polymorphism with poor and hyper-responders
S allele N allele NS genotype
Test of association Test of heterogeneity Test of association Test of heterogeneity Test of association Test of heterogeneity
N OR 95% CI pA pB I2 AM OR 95% CI pA pB I2 AM OR 95% CI pA pB I2 AM
Poor responders
All 11 1.61 0.94-2.74 0.08 <0.0001 80 R 0.95 0.66-1.37 0.78 0.002 65 R 0.93 0.60-1.46 0.75 <0.0001 80 R
Outliers omitted ? 0.90 0.66-1.23 0.52* 0.16 36 F 1.02 0.82-1.26 .88** 0.10 42 F 0.82 0.66-1.02 .08*** 0.78 0 F
NHC 7 1.24 0.76-2.05 0.39 0.03 57 R 0.99 0.60-1.62 0.97 0.009 65 R 0.88 0.69-1.13 0.32 0.79 0 F
Hyper-responders
All 6 1.47 1.05-2.04 0.02 0.23 28 F 0.64 0.46-0.88 0.007 0.19 32 F 1.10 0.83-1.46 0.50 0.37 7 F
NHC 4 1.57 1.11-2.23 0.01 0.33 13 F 0.68 0.38-1.20 0.18 0.07 57 R 1.03 0.76-1.40 0.83 0.69 0 F
NHC: Non-Hispanic Caucasian; N: number of studies; OR: odds ratio; CI: confidence interval; pA: p value for association with significance set at <0.05; pB: p value for heterogeneity with significance set at <0.10; I2 values


















Figure 2 Forest plot of the S680 influence variant on poor ovarian response. Black diamond denotes the pooled OR. Blue squares indicate
the OR in each study, with square sizes directly proportional to the weight contribution (%) of the study. Horizontal lines represent 95% confidence
intervals. Note: In Boudjenah et al. [1], the suffixes A and S indicate overall population and homogeneous subgroup, respectively; In Livshyts
2009, the suffixes C and G indicate control women under 35 years old and over 35 years old, respectively. M-H: Mantel-Haenszel; CI: confidence
interval; df: degree of freedom.
Pabalan et al. Journal of Ovarian Research 2014, 7:122 Page 7 of 11
http://www.ovarianresearch.com/content/7/1/122no associations were changed to likelihood of NS carriers
to be non-hyper-responders with omission of Daelemans
et al [36].
Discussion
With a sample size of 4,020 for the N680S FSHR poly-
morphism, our meta-analysis has shown that the FSHR
gene genotype is important in determining ovarian re-
sponse. The N680S polymorphism has been shown to be
associated with poor and hyper ovarian responses to
stimulation. From the three genotypes, the most and
least likely to be poor and hyper-responders to ovarian
stimulation are SS and NS carriers, respectively. SS
genotype carriers favoring seem to merit higher confi-
dence in the hyper-responder findings than those in
poor responders for two reasons: (i) hyper-responder
findings were generally not heterogeneous which the
poor responder results were. (ii) Sensitivity treatment
showed that poor responder effects were not as robust
as those of the hyper-responders. To our knowledge,
this is the first meta-analysis to address poor and hyper-
responses as indicators of ovarian response. A recentFigure 3 Forest plot of the S680 influence variant on hyper ovarian r
indicate the OR in each study, with square sizes directly proportional to the w
confidence intervals. Note: In Boudjenah et al. [1], the suffixes A and S indicate
Mantel-Haenszel; CI: confidence interval; df: degree of freedom.meta-analysis [22] examined the number of retrieved
oocytes and basal FSH levels based on eight studies, but
not the parameters we used here, except pregnancy
rates in which our findings did not materially differ.
The study-specific findings showed that women homo-
zygous for the FSHR S680 variant were less likely to be
low responders and more likely to be high responders
[1]. In a Chinese study of infertile women, the polymor-
phisms T307A and N680S were associated with ovarian
response to FSH, with the SS genotype having higher
rates of poor response, but not with OHSS [41]. A
retrospective study in IVF patients has shown an asso-
ciation between the presence of the S variant and poor
responses to gonadotropin stimulation, suggesting that
the S680 allele was associated with a diminished sensi-
tivity to FSH [37]. The implication of S680 allele as a
potential marker for predicting poor ovarian response
has been countered with reports suggesting no N680S
association with ovarian response [44]. It has been sug-
gested that the subjects with the NS genotype are more
associated with good response to FSH stimulation,
whereas the subjects with SS and NN genotypes have aesponse. Black diamond denotes the pooled OR. Blue squares
eight contribution (%) of the study. Horizontal lines represent 95%
overall population and homogeneous subgroup, respectively; . M-H:









































Figure 4 Galbraith plot analysis to detect sources of
heterogeneity. LivC: Livshyts C; LivG: Livshyts G; dC3: de Castro et al.
[37]; Hua: Huang; Note: In Livshyts, the suffixes C and G indicate control
women less than 35 years old and over 35 years old, respectively.
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more exogenous FSH for ovarian stimulation [45]. All
these show a lack of consistency in these association
studies outcomes. Here, then, enters the utility of our
meta-analysis.
The observation that the allelic FSH receptor variants
are FSH sensitivity determinants has lead to the hypoth-
esis that certain genetic changes may fine tune the hor-
monal regulation of ovarian physiology, and these can
be attractive markers for various clinical applications in-
cluding optimization of the exogenous FSH dose in ART
(Assisted Reproduction Technique) programs [20,46].
Approximately 20% of women undergoing ovarian stimu-
lation in an IVF program respond poorly to gonadotropin
treatment [47]. Such patients show low concentrations
of serum estradiol, fewer mature oocytes and reduced
pregnancy rates. The basis for low response to gona-
dotropin is not well understood. Diminished ovarianreserve and increased maternal age may be associated
with poor ovarian response [6]. Several parameters such as
poor perifollicular flow [48], presence of ovarian autoanti-
bodies [49] and day 3 serum FSH concentrations [50,51]
have been proposed as ovarian response predictors, but
have not been proven. In some poor responders, increasing
the FSH dose may not help in achieving an increase in
serum estradiol concentrations [52].
Level of FSHR expression also impacts greatly on the
extent of FSH action. FSHR plays a fundamental role in
determining the physiologic FSH responsiveness in the
ovary. Studies suggest that reduced expression affects
FSHR function thereby affecting folliculogenesis [53].
The FSHR reduced expression on granulosa cells has
been shown to be associated with poor ovarian response
[54]. The expression of FSH receptor and its ability to
respond to the exogenous FSH seems to be a gona-
dotropin determinant treatment. Thus, altered FSH
receptor expression and function seems to be a factor
and may account for poor ovarian response. Recently it
has been demonstrated that lower expression of the
FSH receptor may account for poor ovarian response to
gonadotropin stimulation, suggesting a critical role of
FSH receptor in the ovarian response [54].
Interpreting these meta-analysis results would warrant
awareness of its strengths and limitations. Strengths in-
clude: (i) all tissue sources were blood; (ii) most of the
studies addressed the HWE and LD issues; (iii)
consistency in identifying the SS genotype as most likely
to be associated with ovarian response. (iv) Since we did
not include studies which controls deviated from the
HWE, we managed to minimize methodological weak-
ness, such as biased selection of subjects, genotyping er-
rors and population stratification [55].
On the other hand, there are a number of limitations
in our study: (i) we did not address age as covariate of
poor and hyper-response given the insufficiency of
primary data from the included studies. (ii) genotyping
approaches were not uniform, although half of the
studies used real-time PCR (Polymerase Chain Reaction).
It is possible that the N680S polymorphism does not
play any direct functional role in the development of
OHSS, but it is in LD with other polymorphisms. It is
also likely that variants in other than FSHR are relevant
to ovarian response [56]. Variants in genes relevant to
biochemical pathways involved in steroids production
and folliculogenesis have been studied, but replication
of these relationships has been lacking [13,57,58]. Gen-
ome wide association studies may be promising as did a
recent one that found significant correlation with ovarian
response [59]. It is conceivable that ovarian response
related to any one locus will be small due to gene-gene
as well as gene-environment interactions are likely to
operate.
Table 3 Summary of sensitivity analysis findings
Original summary effects Resulting pooled OR
OR 95% CI Nature of association Omitted study [ref] OR 95% CI Effect of study omission
NN genotype poor response overall
0.95 0.66-1.37 no associations Livshyts C [39] 1.05 0.75-1.48 slight likelihood of N carriers being poor responders
0.95 0.66-1.37 no associations Yan [41] 1.03 0.70-1.50 slight likelihood of N carriers being poor responders
SS genotype poor response NHC
1.24 0.76-2.05 S carriers likely to be poor responders Livshyts C [39] 0.98 0.71-1.36 no associations
NN genotype poor response NHC
0.99 0.60-1.62 no associations Livshyts C [39] 1.23 0.93-1.64 likelihood of N carriers being poor responders
0.99 0.60-1.62 no associations Livshyts G [39] 1.12 0.69-1.82 likelihood of N carriers being poor responders
NS genotype hyper-response NHC
1.03 0.76-1.40 no associations Daelemans [36] 0.90 0.60-1.34 slight likelihood of NS carriers being non-hyper-responders

















Pabalan et al. Journal of Ovarian Research 2014, 7:122 Page 10 of 11
http://www.ovarianresearch.com/content/7/1/122Conclusion
Genotyping the FSHR N680S together with some add-
itional markers may provide a means of identifying a
group of poor responders before infertility treatment is
initiated. Meanwhile, further studies regarding other
SNPs (or haplotypes) in the FSHR gene may help better
understand the role of FSHR gene and ovarian re-
sponse. Since potential biases and confounders could
not be ruled out completely in this meta-analysis,
additional large case-control studies or later update
meta-analysis may be warranted to validate or modify
our findings. It would help that well-designed studies
based on sample sizes commensurate with detection of
small genotypic risks should allow more definitive con-
clusions about the association of FSHR polymorphisms
and ovarian response.
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